Related Experiment Video
Updated: Jun 21, 2026
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat
Huaxin Sheng1, Wei Yang, Shiro Fukuda
1The Multidisciplinary Neuroprotection Laboratories, Department of Anesthesiology, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Sustained oxidative stress is a known sequel to focal cerebral ischemia. This study examined the effects of treatment with a single dose or sustained infusion of the redox-modulating MnPorphyrin Mn(III)TDE-2-ImP(5+) on outcome from middle cerebral artery occlusion (MCAO) in the rat. Normothermic rats were subjected to 90 min MCAO followed by 90 min reperfusion and then were treated with a single intracerebroventricular dose of Mn(III)TDE-2-ImP(5+). Neurologic and histologic outcomes were assessed at 1 or 8 weeks postischemia. A single dose of Mn(III)TDE-2-ImP(5+) caused a dose-dependent improvement in histologic and neurologic outcome when assessed 1 week postischemia. Mn(III)TDE-2-ImP(5+) afforded preservation of brain aconitase activity at 5.5 h after reperfusion onset, consistent with its known antioxidant properties. Mn(III)TDE-2-ImP(5+) also attenuated postischemic NF-kappaB activation. Evidence for effects on cerebral infarct size and neurologic function had completely dissipated when rats were allowed to survive for 8 weeks postischemia. In contrast, a 1-week continuous intracerebroventricular Mn(III)TDE-2-ImP(5+) infusion caused persistent and substantive reduction in both cerebral infarct size and neurologic deficit at 8 weeks postischemia. Pharmacologic modulation of postischemic oxidative stress is likely to require sustained intervention for enduring efficacy in improving neurologic and histologic outcome from a transient focal ischemic insult.
Insights
Sustained treatment with MnPorphyrin Mn(III)TDE-2-ImP(5+) significantly improved outcomes after stroke in rats. Short-term treatment was ineffective long-term, highlighting the need for sustained intervention to combat oxidative stress.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Focal cerebral ischemia, such as middle cerebral artery occlusion (MCAO), leads to sustained oxidative stress.
- Oxidative stress plays a critical role in neuronal damage and functional deficits following ischemic stroke.
Purpose of the Study:
- To investigate the therapeutic effects of the redox-modulating agent MnPorphyrin Mn(III)TDE-2-ImP(5+) on outcomes following MCAO in a rat model.
- To determine if a single dose or sustained infusion of Mn(III)TDE-2-ImP(5+) provides enduring neuroprotection.
Main Methods:
- Rats underwent 90 minutes of MCAO followed by 90 minutes of reperfusion.
- Treatment involved either a single intracerebroventricular dose or a continuous 1-week intracerebroventricular infusion of Mn(III)TDE-2-ImP(5+).
- Neurologic and histologic outcomes, including brain aconitase activity and NF-kappaB activation, were assessed at 1 and 8 weeks postischemia.
Main Results:
- A single dose of Mn(III)TDE-2-ImP(5+) improved neurologic and histologic outcomes at 1 week postischemia, preserving brain aconitase activity and attenuating NF-kappaB activation.
- These beneficial effects dissipated by 8 weeks postischemia following a single dose.
- A continuous 1-week infusion of Mn(III)TDE-2-ImP(5+) resulted in persistent reductions in infarct size and neurologic deficits at 8 weeks.
Conclusions:
- Pharmacologic modulation of postischemic oxidative stress requires sustained intervention for long-term efficacy.
- Sustained Mn(III)TDE-2-ImP(5+) infusion offers a promising therapeutic strategy for improving outcomes from transient focal ischemic insults.
